Cardiovascular Disease

CID-103 (TSK011010) is an anti-CD38 antibody that recognizes a unique epitope on CD38. CID-103 can be used in research on immune thrombocytopenia.

PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC₅₀: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC₅₀: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia.

AR-12463 is a derivative of Trapidil (HY-B1016). AR-12463 inhibits the conversion of [14C]acetate to cholesterol. AR-12463 significantly reduces the elevation of total cholesterol in rabbit serum and prevents cholesterol incorporation into tissues. AR-12463 can be used to study atherosclerosis.

Rhazimine is an indole alkaloid that is a dual inhibitor of arachidonic acid metabolism and platelet activating factor-induced platelet aggregation.

Z6466608628 hydrochloride is a selective PPIL4 molecular glue degrader with human PPIL4 EC₅₀ values of 0.34 µM. Z6466608628 hydrochloride functionally recruits PPIL4 to CRBN, induces CRL4^CRBN-mediated ubiquitylation and degradation of PPIL4. Z6466608628 hydrochloride can be used for the research of intracranial aneurysms^[1].

Cinnarizine-d₈ is a deuterium labeled Cinnarizine. Cinnarizine is an antihistamine and a calcium channel blocker.

CLIKKPF is a specific peptide segment. CLIKKPF can bind with phosphatidylserine (PS) in the inner layer of the cell membrane with high affinity. CLIKKPF can enhance the targeting ability of nanoparticles. CLIKKPF can be used for research on cardiovascular conditions.

T 162559 is a potent and selective inhibitor of the Na+/H+ exchanger isoform NHE1 with IC₅₀ values of 0.96 nM. T 162559 does not affect Na+/HCO3- cotransport and Na+/Ca2+ exchange. T 162559 can be used for the research of cardiovascular disease.

Nicergoline-¹³C,d₃ is the ¹³C- and deuterium labeled Nicergoline. Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease.

KMUP-1 is a xanthine derivative with vasodilator activity. KMUP-1 is a inhibitor of phosphodiesterase (PDE) and activator of soluble guanylyl cyclase (sGC). KMUP-1 stimulates NO/sGC/cyclic GMP pathway. KMUP-1 has K⁺ channels opening activity. KMUP-1 ameliorates ischemia-induced cardiomyocyte apoptosis. KMUP-1 can be used for cardiovascular and anti-inflammatory study.

DL-017 is a Quinazoline derivative. DL-017 shows inhibitory constants of approximately 0.90 nM for α1-adrenergic receptors and 404 nM for Na⁺ channels. DL-017 exerts antihypertensive effect.

F1-ispinesib is a heterobifunctional F1-autophagy degrader, composed of an RNA-binding fragment (F1) and the LC3B ligand Ispinesib (HY-50759). F1-ispinesib induces degradation of COL15A1 mRNA via an LC3B-dependent macroautophagy mechanism. F1-ispinesib inhibits cell proliferation and enhances migration of human aortic smooth muscle cells.

SAR296968 is a Na⁺/Ca²⁺ exchanger (NCX) subtype inhibitor with an IC₅₀ value of 74 nM against hNCX1. SAR296968 inhibits both forward and reverse modes of NCX current. SAR296968 enhances cardiac contractility and stroke volume. SAR296968 exerts antiarrhythmic effects. SAR296968 is applicable to research related to heart failure.

D-Glucose 6-phosphate dipotassium is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate dipotassium acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate dipotassium can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.

Antiplatelet agent 3 (Compound K-10) is a compound with anti-platelet aggregation activity. The IC₅₀ values for platelet aggregation induced by ADP, AA and COL are 2.55, 3.22 and 2.09 mg/mL, respectively. Antiplatelet agent 3 is expected to be used in the research of cardiovascular diseases.

(2R)-Atecegatran ((2R)-AZD-0837; (Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab)) is a thrombin inhibitor. (2R)-Atecegatran can be used in research related to thromboembolic disorders.

ZP 120C is a potent and partial ORL1 receptor agonist. ZP 120C inhibits electrically induced contraction. ZP 120C can be used in the research of hyponatremia/hypokalemia.

Cetiedil is a vasodilator and potassium channel blocker with anti-sickle cell and analgesic activities. Cetiedil increases cyclic adenosine monophosphate levels, relaxes vascular smooth muscle, and blocks the action of Bradykinin (HY-P0206). Cetiedil inhibits platelet aggregation, reduces plasma fibrinogen concentration and blood viscosity, suppresses sickling of sickle red blood cells and improves their filterability, and decreases irreversible sickle cells. Cetiedil binds to calmodulin, inhibits Ca²⁺-dependent potassium permeability of erythrocyte membranes, increases sodium permeability of erythrocytes, and regulates polymorphonuclear leukocyte function. Cetiedil can be used in research related to intermittent claudication, arteriosclerosis obliterans, diabetic arteriosclerosis, Raynaud's disease, angina pectoris, and sickle cell anemia.

Flosatidil (SL 85.1016) is an orally active Calcium Channel antagonist. Flosatidil has antianginal and antihypertensive properties.

Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC₅₀ of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.